Septerna Stock / BioTech & PharmaFounded: 2022Funding to Date: $225MM

Septerna is a biochemical drug discovery company. With GPCR scientists, Septerna is focused on researching G protein receptors to develop new medicines in the pharmacology field. The company also features drug-screening technology, modular assemblies, and Silico molecule screening. Septerna was founded by Arthur Christopoulos, Jeffrey Finer, Patrick Sexton, and Robert Lefkowitz in 2022 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on financing and valuation for Septerna, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in


Enterprise Value

Powered by Forge Data

Access Septerna’s valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Septerna.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.


Animation displayed is not current and securities are shown for illustrative purposes only.

Septerna investors also invested in these private companies

Mirae Asset Global Investments
Invus Financial Advisors


Management Team

Jeffrey Finer Ph.D
Co-Founder & Chief Executive Officer
Liz Bhatt
Chief Operating Officer
Samira Shaikhly
Chief People Officer
Ali Masoudi
Co-Founder & Staff Scientist
Arthur Christopoulos Ph.D
Patrick Sexton Ph.D
Robert Lefkowitz MD

Board Members

Abraham Bassan
Samsara BioCapital
Alan Ezekowitz MD
Third Rock Ventures
Jeffrey Tong Ph.D
Third Rock Ventures

Frequently Asked Questions About Septerna’s Stock

Can you buy Septerna’s stock?
Septerna is not publicly traded on NYSE or NASDAQ in the U.S. To buy Septerna’s stock you need to be an accredited investor. Learn more about how to invest in the private market or register today to get started.
Can you sell Septerna’s stock?
Yes, you can sell stock of a private company like Septerna. Forge can help you sell your Septerna stock in a way that works for you and the company. So if you are seeking liquidity, register with us today to get started.
What is Septerna’s stock price?
Septerna is a privately held company and therefore does not have a public stock price. However, you may access Septerna’s private market stock price with Forge Data.
What is Septerna’s stock ticker symbol?
Septerna does not have an official ticker symbol because this company is not currently publicly traded.
Can institutional investors buy and sell private market stocks?
Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

News Highlights

Septerna snags $150M series B for pipeline of GPCR therapies tackling hard-to-drug targets
Septerna has secured $150 million in a series B fundraise, money that will go toward two newly unveiled programs including moving its first G-protein-coupled receptor (GPCR) drug into the clinic.
Updated on: May 23, 2024


Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.